CirrusDx Adds Lab Testing for Recently Approved UTI Antibiotic
The new capability helps clinicians determine if a patient's infection will respond to gepotidacin before prescribing the treatment.
The new capability helps clinicians determine if a patient's infection will respond to gepotidacin before prescribing the treatment.
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
Researchers identify molecular markers in saliva that could lead to new clinical tests for sleep loss.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.